MaxQ Medical Secures $31.5M to Transform Prostate Care
August 24, 2026, 9:37 am
MaxQ Medical secured $31.5 million in Series A funding. This significant investment accelerates development of a pioneering transurethral platform for prostate care. The innovative system integrates advanced ultrasound imaging with targeted tissue therapy. It aims to provide less invasive, urethra-preserving treatments for conditions such as Benign Prostatic Hyperplasia (BPH). Funding fuels team expansion and critical clinical program advancement. MaxQ's technology, rooted in Stanford research, seeks to revolutionize prostate health management and treatment options for millions.
MaxQ Medical, a Sunnyvale, California-based health-tech innovator, announced a substantial Series A funding round. The company raised $31.5 million. This capital infusion will propel the development of its advanced prostate care platform. MaxQ aims to redefine treatment paradigms for prostate diseases.
The funding round saw significant participation. Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures led the investment. Hillside Capital, an existing investor, also contributed. This collective backing underscores confidence in MaxQ's technology and market potential. The company plans to deploy these funds strategically. Resources will expand the team. They will also advance the critical clinical program. This move positions MaxQ for accelerated growth.
MaxQ Medical is developing a groundbreaking transurethral imaging and therapy system. This platform represents a leap forward in prostate health. It combines advanced ultrasound imaging with tissue-selective therapy. This integration occurs within a single, outpatient procedure. The system allows urologists unprecedented visibility inside the prostate. They can deliver individualized treatments with precision.
The technology focuses on crucial patient benefits. It prioritizes urethra preservation. This design minimizes side effects common with existing prostate procedures. These complications include injury, swelling, bleeding. Potential impacts on sexual function are also reduced. MaxQ's system offers a less invasive option. It targets specific prostate tissue. This approach is designed for greater patient comfort and faster recovery.
Benign Prostatic Hyperplasia (BPH) is the initial clinical indication for the MaxQ system. BPH affects millions of men globally. Current treatment options vary. Many carry significant drawbacks. MaxQ’s technology offers a promising alternative. It provides targeted therapy from within the prostate. This precise approach could improve outcomes for BPH patients.
Future applications extend beyond BPH. MaxQ plans to expand into focal therapy for prostate cancer. Prostate cancer remains a major health challenge. The platform also targets broader prostate diagnostics. This includes biopsy and tumor mapping capabilities. Such expansion would create a comprehensive prostate care solution. This broadens the impact of MaxQ’s innovative platform.
The core of MaxQ’s technology originates from extensive research. Decades of Stanford University's semiconductor ultrasound research power the platform. MaxQ Medical is the first spinout from Orchard Ultrasound Innovation. Orchard was established to commercialize Stanford’s ultrasound advancements. This foundation provides a robust scientific bedrock for MaxQ’s innovations.
Pierre Khuri-Yakub played a pivotal role in this lineage. He co-founded Orchard Ultrasound Innovation. Khuri-Yakub serves as its Chief Scientific Officer. He is also a professor emeritus of electrical engineering at Stanford University. Khuri-Yakub is renowned for inventing Capacitive Micromachined Ultrasonic Transducer (CMUT) technology. MaxQ leverages this foundational research. It applies it to an integrated medical platform.
The market demand for improved prostate care is undeniable. Patients currently face difficult treatment choices. Many existing therapies offer limited results. Others present significant side effects. MaxQ's technology addresses these unmet needs. Investors recognize this critical market gap. Olympus Innovation Ventures noted strong demand. They see the need for technologies combining prostate visualization and treatment. S3 Ventures also brings extensive experience in healthcare technology investments.
MaxQ Medical’s system is currently investigational. It is not commercially available in the United States. Clinical validation remains paramount. The company must generate further evidence. This includes demonstrating safety and effectiveness. Ongoing studies will provide this data. Regulatory progress will dictate the timeline for patient access. The latest financing provides essential capital. It supports continued clinical development.
Ultimately, MaxQ Medical envisions a broader prostate care platform. This platform will integrate treatment, diagnostics, and targeted cancer therapies. Such an integrated system could significantly advance prostate health management. The company's commitment to clinical evaluation remains firm. Team expansion will support these efforts. MaxQ is poised to revolutionize the landscape of prostate care. This new funding brings that vision closer to reality.
MaxQ Medical, a Sunnyvale, California-based health-tech innovator, announced a substantial Series A funding round. The company raised $31.5 million. This capital infusion will propel the development of its advanced prostate care platform. MaxQ aims to redefine treatment paradigms for prostate diseases.
The funding round saw significant participation. Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures led the investment. Hillside Capital, an existing investor, also contributed. This collective backing underscores confidence in MaxQ's technology and market potential. The company plans to deploy these funds strategically. Resources will expand the team. They will also advance the critical clinical program. This move positions MaxQ for accelerated growth.
MaxQ Medical is developing a groundbreaking transurethral imaging and therapy system. This platform represents a leap forward in prostate health. It combines advanced ultrasound imaging with tissue-selective therapy. This integration occurs within a single, outpatient procedure. The system allows urologists unprecedented visibility inside the prostate. They can deliver individualized treatments with precision.
The technology focuses on crucial patient benefits. It prioritizes urethra preservation. This design minimizes side effects common with existing prostate procedures. These complications include injury, swelling, bleeding. Potential impacts on sexual function are also reduced. MaxQ's system offers a less invasive option. It targets specific prostate tissue. This approach is designed for greater patient comfort and faster recovery.
Benign Prostatic Hyperplasia (BPH) is the initial clinical indication for the MaxQ system. BPH affects millions of men globally. Current treatment options vary. Many carry significant drawbacks. MaxQ’s technology offers a promising alternative. It provides targeted therapy from within the prostate. This precise approach could improve outcomes for BPH patients.
Future applications extend beyond BPH. MaxQ plans to expand into focal therapy for prostate cancer. Prostate cancer remains a major health challenge. The platform also targets broader prostate diagnostics. This includes biopsy and tumor mapping capabilities. Such expansion would create a comprehensive prostate care solution. This broadens the impact of MaxQ’s innovative platform.
The core of MaxQ’s technology originates from extensive research. Decades of Stanford University's semiconductor ultrasound research power the platform. MaxQ Medical is the first spinout from Orchard Ultrasound Innovation. Orchard was established to commercialize Stanford’s ultrasound advancements. This foundation provides a robust scientific bedrock for MaxQ’s innovations.
Pierre Khuri-Yakub played a pivotal role in this lineage. He co-founded Orchard Ultrasound Innovation. Khuri-Yakub serves as its Chief Scientific Officer. He is also a professor emeritus of electrical engineering at Stanford University. Khuri-Yakub is renowned for inventing Capacitive Micromachined Ultrasonic Transducer (CMUT) technology. MaxQ leverages this foundational research. It applies it to an integrated medical platform.
The market demand for improved prostate care is undeniable. Patients currently face difficult treatment choices. Many existing therapies offer limited results. Others present significant side effects. MaxQ's technology addresses these unmet needs. Investors recognize this critical market gap. Olympus Innovation Ventures noted strong demand. They see the need for technologies combining prostate visualization and treatment. S3 Ventures also brings extensive experience in healthcare technology investments.
MaxQ Medical’s system is currently investigational. It is not commercially available in the United States. Clinical validation remains paramount. The company must generate further evidence. This includes demonstrating safety and effectiveness. Ongoing studies will provide this data. Regulatory progress will dictate the timeline for patient access. The latest financing provides essential capital. It supports continued clinical development.
Ultimately, MaxQ Medical envisions a broader prostate care platform. This platform will integrate treatment, diagnostics, and targeted cancer therapies. Such an integrated system could significantly advance prostate health management. The company's commitment to clinical evaluation remains firm. Team expansion will support these efforts. MaxQ is poised to revolutionize the landscape of prostate care. This new funding brings that vision closer to reality.